European pricing mechanism not working well for rare medicines
- European rules should ensure that rare, expensive medicines eventually fall in price.
- That doesn't happen, researchers conclude. Competition is absent and so prices remain high.
- Spending on 'orphan drugs' will only increase. That's why the researchers are calling for new policies.
To give pharmaceutical companies the chance to recoup development costs of rare drugs, they are granted exclusivity. When that expires, the price should drop, but that does not happen. An untenable situation, researchers warn.
fd.nl
%3Aformat(jpeg)%3Abackground_color(fff)%2Fhttps%253A%252F%252Fwww.metronieuws.nl%252Fwp-content%252Fuploads%252F2025%252F05%252Fnaam-tattoo.jpg&w=3840&q=100)
%3Aformat(jpeg)%3Abackground_color(fff)%2Fhttps%253A%252F%252Fwww.metronieuws.nl%252Fwp-content%252Fuploads%252F2025%252F05%252Fhuwelijk-trouwen.jpg&w=3840&q=100)